ArticleOpen veterinary journal2026
Comparative effects of raw and commercialized edible bird's nest products on low-density lipoprotein receptor expression and cholesterol regulation in HepG2 cells.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Edible bird's nest (EBN), produced by swiftlets from salivary gland secretions, is a valuable glycoprotein source that offers significant nutritional benefits, particularly influencing consumer health lipid metabolism. Cleaning, bleaching, drying, and enzyme-based techniques can alter the physical quality, nutritional value, and bioactive characteristics of EBN. Aim: This study aimed to compare the effects of raw and commercialized EBN extracts on cell viability, total cellular cholesterol (TCC), and LDLR gene expression in HepG2 cells. Methods: HepG2 cells were cultured under controlled laboratory conditions and treated with graded concentrations of EBN extracts. Cell viability was evaluated using MTT assay. Enzymatically, intracellular cholesterol levels were quantified, and LDLR gene expression was measured using reverse transcription quantitative PCR. Results: Raw EBN maintained higher cell viability and exhibited a nonlinear dose-response pattern, whereas commercialized EBN produced a clear dose-dependent cytotoxic effect. Both raw and commercialized EBN markedly upregulated LDLR gene expression, increasing transcription by approximately 23-fold and 24.5-fold, respectively, compared with untreated controls. Total cellular cholesterol did not differ significantly ( Conclusion: Both raw and commercialized EBN significantly enhance LDLR gene expression in HepG2 cells, indicating their potential to promote cholesterol uptake. However, processing may alter the biochemical composition and biological activity of EBN, contributing to differences in cytotoxicity and cholesterol response. These findings provide molecular insights into the potential of EBN as a functional food for cholesterol regulation and highlight the importance of processing integrity in preserving its bioactive efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.